The Oncology Institute, Inc. (NASDAQ:TOI) Sees Significant Increase in Short Interest

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 934,800 shares, a growth of 188.3% from the January 31st total of 324,300 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average trading volume of 1,970,000 shares, the short-interest ratio is presently 0.5 days.

Oncology Institute Price Performance

NASDAQ:TOI traded down $0.04 during trading hours on Friday, reaching $0.85. The company had a trading volume of 301,543 shares, compared to its average volume of 870,819. The stock has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.41. Oncology Institute has a one year low of $0.13 and a one year high of $2.10. The firm has a market capitalization of $64.38 million, a PE ratio of -1.09 and a beta of 0.37. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91.

Institutional Trading of Oncology Institute

A number of large investors have recently bought and sold shares of the stock. HighTower Advisors LLC grew its holdings in shares of Oncology Institute by 190.8% during the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after purchasing an additional 53,382 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after purchasing an additional 109,769 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Oncology Institute during the fourth quarter worth $41,000. Renaissance Technologies LLC grew its holdings in shares of Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares during the last quarter. Finally, FreeGulliver LLC grew its holdings in shares of Oncology Institute by 219.3% during the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after purchasing an additional 412,578 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.